Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
December 2013

Season's Greetings
Pharmacogenomics may soon provide the key to personalizing medication treatments for each individual patient.

Vortioxetine (Brintellix)
The new antidepressant vortioxetine (Brintellix) is more efficacious than placebo, but whether it has added benefits that will justify its higher cost compared with generic antidepressants has yet to be determined.

Vitamin D and Psychiatric Patients
Patients with chronic mental illness who are deficient in vitamin D should receive nutritional supplements.

Antipsychotics in Dementia: Another Look
Higher doses of antipsychotic drugs seem to increase the risk of death in patients with dementia, but lower doses might not.

In Brief
Both Benzodiazepines and Nonbenzodiazepine Hypnotic Medications Are Associated with an Increased Risk of Fractures

CME 2013
Please be sure to review the Continuing Medical Education (CME) posttest and evaluation for 2013, inserted in this month's issue.

Season's Greetings

December 2013

As 2013 draws to an end, I eagerly anticipate 2014 and the exciting research that will inform psychiatric practice in the years ahead. For example, several of my colleagues at Penn State are studying pharmacogenomics. They aim to personalize medication treatment by quantifying the activity of each…

To view the rest of this article, please: